Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
about
Pharmaceutical policies: effects of cap and co-payment on rational use of medicinesInformation and shared decision-making are top patients' prioritiesSystematic review on quality control for drug management programs: is quality reported in the literature?Coverage of atypical antipsychotics among medicare drug plans in the state of washington: changes between 2007 and 2008.Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetesEntering and exiting the Medicare part D coverage gap: role of comorbidities and demographicsSensitivity of medication use to formulary controls in medicare beneficiaries: a review of the literature.Pharmaceutical cost management and access to psychotropic drugs: the U.S. contextFactors influencing cost-related nonadherence to medication in older adults: a conceptually based approachAssociation of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.Who can't pay for health care?Coping strategies used by patients infected with hepatitis C virus who are facing medication costs.Did Medicare Part D reduce disparities?Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different statesHow patient cost-sharing trends affect adherence and outcomes: a literature review.Provider views about responsibility for medication adherence and content of physician-older patient discussionsRace/ethnicity and nonadherence to prescription medications among seniors: results of a national studyThe demise of Oregon's Medically Needy program: effects of losing prescription drug coverage.Patients at-risk for cost-related medication nonadherence: a review of the literature.Angiotensin receptor blockers on the formularies of Medicare drug plans.Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions.Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverageCost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries.Association of Medicare Part D medication out-of-pocket costs with utilization of statin medicationsOut-of-pocket medication costs and use of medications and health care services among children with asthma.Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes.Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance programOlder patients' perceptions of medication importance and worth: an exploratory pilot study.Medication assistance programs: do all in need benefit equally?Digesting the doughnut hole.Pharmaceuticals companies' medication assistance programs: potentially useful but too burdensome to use?Medicare Part D coverage gap: race, gender, and cost-related medication nonadherence.The Effect of a Cardiovascular Polypill Strategy on Pill Burden.What Strategies Do Physicians and Patients Discuss to Reduce Out-of-Pocket Costs? Analysis of Cost-Saving Strategies in 1,755 Outpatient Clinic Visits.Is bigger better? An argument for very low starting doses.Drug licenses: a new model for pharmaceutical pricingWhat does the Medicare prescription drug legislation mean for the American cardiologist?How end-stage renal disease patients manage the Medicare Part D coverage gap.Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study.
P2860
Q24188009-29DA0C3D-AB81-43C2-939A-4DC5D3BE0DE3Q33235030-42FC9ABD-E119-46E6-86E9-614F90AA8EB4Q33412577-C01D795F-8AB2-47A7-89FD-850B8EED549AQ33587010-409517E4-BFC8-4C97-B84D-D347FEA49550Q33725773-7A006A7B-F373-4EE1-9DAB-25C1F77A7B32Q33848964-E84DB5D8-40B6-4834-A738-B65946F253E4Q33931960-AA24CB90-0F4B-467A-AD2A-2BB5009786CAQ34390982-70D7CC13-CACD-4564-95AB-6B574D0A7E1AQ34454355-9AB2FD3B-D126-423B-9A7C-99EAAA1884DEQ34529920-EE2FBA10-E8DC-43E7-A29A-DB211E63D1B6Q34723262-FBE14613-2672-4AA2-941F-8872B1757A79Q34977603-5D9E14FA-B7A2-4FA6-B6FC-CB0254ECA72BQ35509973-5F4D185B-F344-4364-911D-1BED1A18989CQ35683030-1068ACF6-41B2-4635-B81F-F2238B89B855Q35752951-FDC8B1B8-2272-4E23-8C7D-7009421DF7A7Q36053545-FA50E018-6F25-44C4-BF81-15D0850F2C06Q36416879-DF7CEF68-068F-480B-B671-94AA975477B2Q36417035-E0E8AD42-1C81-4261-A4F8-11FAEB89E0A4Q36417054-35EFF758-27E0-4C67-BC56-81B47E765CA2Q36552000-B813AB80-8385-4F9F-A5CC-CB2B5F71A1CEQ36666594-A14B9A5A-88B5-4A62-A1EB-B94A48D7827DQ36741634-AB5DF834-BC83-43D9-AEBC-618C09F54380Q36927439-5D05C6F1-43D4-42FF-B0BB-79075475FB5AQ37050954-A4D4A27B-E4E5-42CB-A6AF-F5B5DFFADF90Q37125842-9DA695ED-B39A-4E7A-BB0F-90D06207EF44Q37191246-F3FFBF81-2D5E-4A40-9308-B80DF7FDB0EFQ37194648-5BED4DB1-DEB6-454B-B4AF-28918734446AQ37236459-02F57933-C536-4971-A8FB-64C0C2AEB22DQ37355509-C56E628D-5B20-492E-B165-358FAC86EAECQ37372058-228AAEAA-B153-420F-832E-32A3B0BA81A4Q37374576-0AF00CD9-7BE1-4A4B-AC7A-AFF1B063BD52Q37380436-7EC57794-CCF6-459E-BCDE-6DB5048C2B59Q38977081-0F621253-88C4-4396-9840-8BFCEDEC80CEQ41477116-55008B97-8FE2-4F8D-9E74-16E3887DEBDCQ41652859-C63D3D78-D215-4D72-88B4-EAD72196C73FQ41677088-061C06F0-5D5E-4AD4-9500-B79B9438A128Q42576240-C78F2A06-44C4-4A38-82D0-D7EF4D739379Q44333941-C12859A0-513F-4AB7-8591-BA0128A2C91AQ44982031-964B3EA3-AC96-4C35-A0F5-17DC82C9894FQ45122916-3E41E734-9BF2-4B4C-9FA8-062BA198247A
P2860
Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Cost-lowering strategies used ...... d have a gap in drug coverage.
@en
Cost-lowering strategies used ...... d have a gap in drug coverage.
@nl
type
label
Cost-lowering strategies used ...... d have a gap in drug coverage.
@en
Cost-lowering strategies used ...... d have a gap in drug coverage.
@nl
prefLabel
Cost-lowering strategies used ...... d have a gap in drug coverage.
@en
Cost-lowering strategies used ...... d have a gap in drug coverage.
@nl
P2093
P356
P1476
Cost-lowering strategies used ...... d have a gap in drug coverage.
@en
P2093
Carol M Mangione
Chien-Wen Tseng
Emmett Keeler
Robert H Brook
W Neil Steers
P304
P356
10.1001/JAMA.292.8.952
P407
P577
2004-08-01T00:00:00Z